Immune checkpoint inhibitors: a patent review (2010-2015)

References

• Hoption Cann SA, Van Netten JP, Van Netten C, et al. Coley and tumour regression: a place in history or in the future. Postgrad Med J. 2003;79:672–680.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Scheibenbogen C, Marincola FM, et al. Natural T cell immunity against cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2003;9:4296–4303.
   PubMed Web of Science ®Google Scholar
• Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121:1–14.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–242.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–264.
   PubMed Web of Science ®Google Scholar
• Markets R and. Global Immune Checkpoint Inhibitors Market 2015-2025 - Immune Checkpoint Inhibitors Set to Be a Multi-billion Dollar Market. n.d. [ cited 6 Feb 2016]. Available from: http://www.prnewswire.com/news-releases/global-immune-checkpoint-inhibitors-market-2015-2025—immune-checkpoint-inhibitors-set-to-be-a-multi-billion-dollar-market-300161098.html
   Google Scholar
• Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the Pd-1 immunoinhibitory receptor by a Novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–1034.
   PubMed Web of Science ®Google Scholar
• Storz U. Intellectual property issues of immune checkpoint inhibitors. Mabs. 2016;8:10–26.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–1639.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Brahmer J. Nivolumab in nonsquamous non-small-cell lung cancer. N Engl J Med. 2016;374:493–494.
   PubMed Web of Science ®Google Scholar
• Gyawali B, Ota A, Ando Y. Nivolumab in nonsquamous non-small-cell lung cancer. N Engl J Med. 2016;374:493.
   PubMedGoogle Scholar
• Hasegawa T, Uno H, Wei L-J. Nivolumab in nonsquamous non-small-cell lung cancer. N Engl J Med. 2016;374:492–493.
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Pfizer Inc., Merck Sharp & Dohme Corp. Combination of a Pd-1 Antagonist and a Vegfr inhibitor for treating cancer. WO2015119930. 2015.
   Google Scholar
• Genentech, Inc. F. Hoffmann-La Roche Ag methods of treating cancer using Pd-L1 axis binding antagonists and vegf antagonists. WO2013181452. 2013.
   Google Scholar
• Glaxosmithkline Llc, Merck Sharp & Dohme Corp. Treating cancer with a combination of a Pd-1 antagonist and a vegfr inhibitor. WO2015088847. 2015.
   Google Scholar
• Amplimmune, Inc. Compositions of Pd-1 antagonists and methods of use. WO2010027423. 2010.
   Google Scholar
• Amplimmune, Inc. Pd-1 antagonists and methods of use thereof. WO2010027828. 2010.
   Google Scholar
• Amplimmune, Inc. Antibodies and other molecules that bind B7-H1 and Pd-1. WO2012145493. 2012.
   Google Scholar
• Anaptysbio, Inc. Antibodies directed against programmed death-1 (pd-1). WO2014179664. 2014.
   Google Scholar
• The Brigham And Women’s Hospital. Inc Bi-specific antibodies against tim-3 and Pd-1 for immunotherapy in chronic immune conditions. WO2011159877. 2011.
   Google Scholar
• Dana–Farber Cancer Institute, Inc. Novartis Ag, president and fellows of Harvard College Antibody Molecules to Pd-1 and uses thereof. WO2015112900. 2015.
   Google Scholar
• Isis Innovation Limited Pd-1 Specific Antibodies and Uses Thereof. WO2010029434. 2010.
   Google Scholar
• sis Innovation Limited. Pd-1 specific antibodies and uses thereof. WO2010029435. 2010.
   Google Scholar
• Merck Sharp & Dohme Corp Stable Formulations of Antibodies to Human Programmed Death Receptor Pd-1 and Related Treatments. WO2012135408. 2012.
   Google Scholar
• Universite De La Mediterranee, Inserm (Institut National De La Sante Et De La Recherche Medicale). Pd-1 antibodies and Pd-L1 antibodies and uses thereof. WO2010089411. 2010.
   Google Scholar
• B Macrogenics, Inc. Covalently bonded diabodies having immunoreactivity with Pd-1 and Lag-3, and methods of use thereof. WO2015200119. 2015.
   Google Scholar
• Medimmune Limited. Antibodies against Pd-1 and uses thereof. WO2015036394. 2015.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Human antibodies to Pd-1. WO2015112800. 2015.
   Google Scholar
• Suzhou Stainwei Biotech Inc. Monoclonal antibody for antagonizing and inhibiting binding of programmed death (pd-1) to ligand thereof and coding sequence and use thereof. WO2015058573. 2015.
   Google Scholar
• Ucb Pharma. S.A. Pd-1 antibody. WO2011110604. 2011.
   Google Scholar
• R-Pharm Overseas, Inc. Pd-L1 antagonist fully human antibody. WO2015195163. 2015.
   Google Scholar
• Regeneron Pharmaceuticals, Inc. Human antibodies to Pd-L1. WO2015112805. 2015.
   Google Scholar
• Spring Bioscience Corporation. F. Hoffmann-La Roche Ag Pd-L1 antibodies and uses thereof. WO2015181342. 2015.
   Google Scholar
• Merck Sharp & Dohme Corp. Antibodies that bind to human programmed death ligand 1 (pd-L1). WO2014100079. 2014.
   Google Scholar
• Dana–Farber Cancer Institute, Inc. Human monoclonal Anti-Pd-L1 antibodies and methods of use. WO2014055897. 2014.
   Google Scholar
• Dana–Farber Cancer Institute, Emory University Human Anti-Pd-1, Pd-L1, and Pd-L2 Antibodies and Uses Therefor. WO2010036959. 2010.
   Google Scholar
• Genentech, Inc. F.Hoffman-La Roche Ag compositions for treating cancer using Pd-1 axis binding antagonists and mek inhibitors. WO2016011160. 2016.
   Google Scholar
• Christopher Rudd Use of Gsk-3 Inhibitors or Activators Which Modulate Pd-1 or T-Bet Expression to Modulate T Cell Immunity. WO2015155738. 2015.
   Google Scholar
• Pfizer Inc., Merck Sharp& Dohme Corp. Combination of a Pd-1 antagonist and a 4-Abb agonist for treating cancer. WO2015119923. 2015.
   Google Scholar
• Genentech, Inc. F. Hoffmann-La Roche Ag methods of treating cancer using Pd-1 axis binding antagonists and mek inhibitors. WO2013019906. 2013.
   Google Scholar
• Incyte Corporation, Merck Sharp and Dohme Corp. Combination of a Pd-1 antagonist and an ido1 inhibitor for treating cancer. WO2015119944. 2015.
   Google Scholar
• Genentech, Inc. F. Hoffmann-La Roche Ag methods of treating cancer using Pd-1 axis binding antagonists and tigit inhibitors. WO2015009856. 2015.
   Google Scholar
• The Trustees Of The University Of Pennsylvania, Inovio Pharmaceuticals, Inc. Pd1 and Pdl1 antibodies and vaccine combinations and use of same for immunotherapy. WO2015103602. 2015.
   Google Scholar
• Genentech, Inc. F. Hoffmann-La Roche Ag methods of treating cancers using Pd-1 axis binding antagonists and taxanes. WO2015095404. 2015.
   Google Scholar
• Genentech, Inc. F. Hoffmann-La Roche Ag combination therapy comprising Ox40 binding agonists and Pd-1 axis binding antagonists. WO2015095423. 2015.
   Google Scholar
• Genentech, Inc. F. Hoffmann-La Roche Ag methods of treating cancer using Pd-1 axis binding antagonists and an Anti-Cd20 antibody. WO2015095410. 2015.
   Google Scholar
• Ribas A, Kefford R, Marshall MA, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013;31:616–622.
   PubMed Web of Science ®Google Scholar
• Antitope Ltd Humanised Anti Ctla-4 Antibodies. WO2012120125. 2012.
   Google Scholar
• Alligator Bioscience Ab Bispecific Molecules Capable of Specifically Binding to Both Ctla-4 and Cd40. WO2014207064. 2014.
   Google Scholar
• The University Court Of The University Of Aberdeen Antibodies Specifically Directed to the Soluble Form of Ctla-4. WO2010097597. 2010.
   Google Scholar
• Liu X, Shin N, Koblish HK,et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115:3520–3530.
   PubMed Web of Science ®Google Scholar
• Opitz CA, Litzenburger UM, Opitz U, et al. The indoleamine-2,3-dioxygenase (IDO) inhibitor 1-methyl-D-tryptophan upregulates IDO1 in human cancer cells. PloS One. 2011;6:e19823.
   PubMed Web of Science ®Google Scholar
• Muller AJ, Prendergast GC. Marrying immunotherapy with chemotherapy: why say IDO? Cancer Res. 2005;65:8065–8068.
   PubMed Web of Science ®Google Scholar
• Newlink Genetics Corporation Fused Imidazole Derivatives Useful as Ido Inhibitors. WO2012142237. 2012.
   Google Scholar
• Bristol-Myers Squibb Company Inhibitors of Indoleamine 2,3-Dioxygenase (ido). WO2014150677. 2014.
   Google Scholar
• Bristol-Myers Squibb Company Ido Inhibitors. WO2014150646. 2014.
   Google Scholar
• Bristol-Myers Squibb Company Ido Inhibitors. WO2015031295. 2015.
   Google Scholar
• Bristol-Myers Squibb Company Ido Inhibitors. WO2015006520. 2015.
   Google Scholar
• Bristol-Myers Squibb Company Ido Inhibitors. WO2015002918. 2015.
   Google Scholar
• Ludwig Institute For Cancer Research Ltd Ido Inhibitors and Therapeutic Uses Thereof. WO2011045340. 2011.
   Google Scholar
• Hastings WD, Anderson DE, Kassam N, et al. TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol. 2009;39:2492–2501.
   PubMed Web of Science ®Google Scholar
• Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005;6:1245–1252.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, Von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-Mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71:3540–3551.
   PubMed Web of Science ®Google Scholar
• Novartis Ag, Children’s Medical Center Corporation, Dana–Farber Cancer Institute, Inc. Antibody molecules to Tim-3 and uses thereof. WO2015117002. 2015.
   Google Scholar
• Kyowa Hakko Kirin Co., Ltd., Kyushu University, National University Corporation. Anti-Tim-3 antibody. WO2011155607. 2011.
   Google Scholar
• Cellerant Therapeutics, Inc. Antibodies that specifically bind to Tim3. WO2013006490. 2013.
   Google Scholar
• Institute Of Basic Medical Science, The Academy Of Military Medical Science Of The Chinese Pla, Human Tim-3 fusion protein capable of blocking Tim-3 signaling pathway. WO2015109931. 2015.
   Google Scholar
• Andreae S, Piras F, Burdin N, et al. Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol Baltim Md 1950. 2002;168:3874–3880.
   Google Scholar
• Bristol-Myers Squibb Company Optimization of Antibodies That Bind Lymphocyte Activation Gene-3 (lag-3), and Uses Thereof. WO2014008218. 2014.
   Google Scholar
• Medarex, Inc. Human antibodies that bind lymphocyte activation Gene-3 (lag-3), and uses thereof. WO2010019570. 2010.
   Google Scholar
• Novartis A, Immutep SA Antibody molecules to Lag-3 and uses thereof. WO2015138920. 2015.
   Google Scholar
• Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function. Cancer Cell. 2014;26:923–937.
   PubMed Web of Science ®Google Scholar
• Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents. WO2014089169. 2014.
   Google Scholar
• Genentech, Inc. F. Hoffman-La Roche Ag methods of treating cancer using tigit inhibitors and anti-cancer agents. WO2016011264. 2016.
   Google Scholar
• Genentech, Inc. F. Hoffmann-La Roche Ag methods of treating cancer using Pd-1 axis binding antagonists and tigit inhibitors. WO2015009856. 2015.
   Google Scholar
• Watanabe N, Gavrieli M, Sedy JR, et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol. 2003;4:670–679.
   PubMed Web of Science ®Google Scholar
• Han P, Goularte OD, Rufner K, et al. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol Baltim Md 1950. 2004;172:5931–5939.
   Google Scholar
• Gonzalez LC, Loyet KM, Calemine-Fenaux J, et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci U S A. 2005;102:1116–1121.
   PubMed Web of Science ®Google Scholar
• Sedy JR, Gavrieli M, Potter KG, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005;6:90–98.
   PubMed Web of Science ®Google Scholar
• Gertner-Dardenne J, Fauriat C, Orlanducci F, et al. The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood. 2013;122:922–931.
   PubMed Web of Science ®Google Scholar
• INSERM (Institut National de la Santé et de la Recherche Médicale). Institut Jean Paoli & Irene Calmettes, Université D’aix-Marseille, Antagonist of the Btla/Hvem interaction for use in therapy. WO2014184360. 2014.
   Google Scholar
• N.V. Organon, Medarex, Inc. Fully human antibodies to btla. WO2011014438. 2011.
   Google Scholar
• Universite De La Mediterranee, INSERM (Institut National de la Santé et de la Recherche Médicale). Btla antibodies and uses thereof. WO2010106051. 2010.
   Google Scholar
• Wang L, Rubinstein R, Lines JL,et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J Exp Med. 2011;208:577–592.
   PubMed Web of Science ®Google Scholar
• Le Mercier I, Chen W, Lines JL, et al. VISTA regulates the development of protective antitumor immunity. Cancer Res. 2014;74:1933–1944.
   PubMed Web of Science ®Google Scholar
• Green KA, Wang L, Noelle RJ, et al. Use of vista agonists and antagonists to suppress or enhance humoral immunity. WO2015191881. 2015.
   Google Scholar
• Noelle R, Ceeraz S, Lemercier I, et al. Vista antagonist and methods of use. WO2015109340. 2015.
   Google Scholar
• Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature. 2001;409:97–101.
   PubMed Web of Science ®Google Scholar
• Janke M, Witsch EJ, Mages HW, et al. Eminent role of ICOS costimulation for T cells interacting with plasmacytoid dendritic cells. Immunology. 2006;118:353–360.
   PubMed Web of Science ®Google Scholar
• Ito T, Yang M, Wang Y-H, et al. Plasmacytoid dendritic cells prime IL-10–producing T regulatory cells by inducible costimulator ligand. J Exp Med. 2007;204:105–115.
   PubMed Web of Science ®Google Scholar
• Faget J, Bendriss-Vermare N, Gobert M, et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res. 2012;72:6130–6141.
   PubMed Web of Science ®Google Scholar
• INSERM (Institut National de la Santé et de la Recherche Médicale). Institut Jean Paoli & Irene Calmettes, Université D’aix-Marseille, Antibodies Directed Against Icos and uses thereof. WO2012131004. 2012.
   Google Scholar
• Medimmune. Llc antibody formulation. WO2010056804. 2010.
   Google Scholar
• Speiser DE, Pittet MJ, Valmori D, et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma–specific cytolytic T lymphocytes. J Exp Med. 1999;190:775–782.
   PubMed Web of Science ®Google Scholar
• Yu J, Venstrom JM, Liu X-R, et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell–depleted allogeneic hematopoietic cell transplantation. Blood. 2009;113:3875–3884.
   PubMed Web of Science ®Google Scholar
• Innate Pharma Anti-Kir3d Antibodies. WO2010081890. 2010.
   Google Scholar
• Innate Pharma Kir3dl2 Binding Agents. WO2014044686. 2014.
   Google Scholar
• Romagné F, André P, Spee P, et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood. 2009;114:2667–2677.
   PubMed Web of Science ®Google Scholar
• Bastid J, Cottalorda-Regairaz A, Alberici G, et al. ENTPD1/CD39 is a promising therapeutic target in oncology. Oncogene. 2013;32:1743–1751.
   PubMed Web of Science ®Google Scholar
• Bastid J, Regairaz A, Bonnefoy N, et al. Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity. Cancer Immunol Res. 2015;3:254–265.
   PubMed Web of Science ®Google Scholar
• Orega Biotech Antibodies Against Human Cd39 and Use Thereof. WO2012085132. 2012.
   Google Scholar
• Zitvogel L, Galluzzi L, Viaud S, et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med. 2015;7:271ps1.
   PubMed Web of Science ®Google Scholar
• Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350:1079–1084.
   PubMed Web of Science ®Google Scholar
• Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J Pathol. 2014;232:199–209.
   PubMed Web of Science ®Google Scholar
• Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016 Jan 19;4:3.
   Web of Science ®Google Scholar